- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2018–2023 · research · R01
Resistance and Sensitivity to MET Inhibitors in Lung Cancer
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · research · R21
Targeting the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational Oncology
David Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
The Role of E2F2 in HER2 Positive Breast Cancer
Jonathan Rennhack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
End-of-Life Care for Adolescents and Young Adults with Cancer: An Evaluation of Care and Development of Patient-Centered Quality Measures
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · fellowship · F32
Obesity, Molecular Biomarkers, and Multiple Myeloma Prognosis
Catherine Marinac · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
NMR-based dynamic assessment of TCR transmembrane conformational states linked to T cell function
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · grant · KCRP
Predictive Biomarkers for Nivolumab Treatment in Metastatic Renal Cell Carcinoma
Toni Choueiri · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2023 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy
Yana Pikman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K00
Metabolically active macrophages: a novel link between obesity and triple negative breast cancer
Payal Tiwari · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · grant · Continuing Grant
Statistical Methods for Multi-Study Predictions
Giovanni Parmigiani · Dana-Farber Cancer Institute · funded by National Science Foundation
2018–2023 · cooperative agreement · UH3
Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training
James A. Tulsky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
Robert J Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R01
The Role of RHOA in Diffuse Gastric Cancer
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · award
Resilience Outcomes among Adolescents and Young Adults with Advanced Cancer
Abby Rosenberg · Dana-Farber Cancer Institute · funded by American Cancer Society
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy
Yana Pikman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R01
Effects of marijuana use on inflammation and vascular injury in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · U01
Rewiring of regulatory networks in breast cancer by transcription factor isoforms
Martha L Bulyk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
The Role of RHOA in Diffuse Gastric Cancer
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · research · R03
Preventing Secondary Skin Cancer in Young Adult Cancer Survivors
Christopher John Recklitis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
End-of-Life Care for Adolescents and Young Adults with Cancer: An Evaluation of Care and Development of Patient-Centered Quality Measures
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · U01
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K08
Targeting casein kinase 1-alpha for cancer therapy
Steven Muntean Corsello · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · career development · Career Development Award
Dissecting inherited and acquired genetic mediators of testicular germ cell tumor (TGCT) initiation and progression
Saud Aldubayan · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2018–2023 · research · R01
Effects of marijuana use on inflammation and vascular injury in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
Robert J Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · research · R21
Physical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccines
Derin B Keskin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · research · R21
Physical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccines
Derin B Keskin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Andrew A Lane · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · program · P20
Precision Interception of Aggressive Prostate Cancer in African American Men
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · career development · K00
Investigating molecular mechanism of immune response during cancer progression
Zeyu Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · career development · K00
Investigating molecular mechanism of immune response during cancer progression
Zeyu Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · research · R01
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
Rochelle Bagatell · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · grant · BCRP
Targeting CDK4/6 in HER2-Positive Breast Cancer Brain Metastasis
Jean Zhao · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2024 · research · Former Investigator
Benjamin L. Ebert, MD — HHMI Former Investigator (2018-2024)
Benjamin L. Ebert, Md · Dana-Farber Cancer Institute · funded by Howard Hughes Medical Institute
